- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Accelerate Product Innovation & Availability
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
The next installment of our Px Pulse series Research Fundamentals, explaining key concepts in HIV prevention research, is up. In this episode, Px Pulse host Jeanne Baron and Matthew Rose, a veteran HIV advocate and now Director at Global Health Strategies, look at endpoints in research.
Endpoints are a crucial component in every clinical trial but they are not always well understood. In addition, advocates can and should play a role, reviewing endpoints and interrogating how well the trial will serve communities that need HIV prevention.
Joining us to explore all this are:
- Dave Glidden, Professor of Epidemiology & Bio-statistics at UC San Francisco
- Erica Lessem, Senior Strategist for NYC Dept. of Health and Mental Hygiene, former Deputy Executive Director, Treatment Action Group
- Meagan O’Brien, Senior Medical Director of Early Clinical Development & Clinical Experimental Sciences at Regeneron
Listen to learn how endpoints are used in clinical research, why they change overtime, and what matters most about endpoints for advocates and researchers alike.
Listen
Transcript
Previous Research Fundamentals
Endpoints are one element in evolving trial design for HIV prevention. Go to our dedicated page on trial design for more information and resources to engage with this fast-changing area.